Shots:

• Halozyme to receive $40M up front for exclusively license 4 HIV small & large molecule targets and is eligible to receive ~$175M as development & commercial milestones per target- following the achievement of certain milestones along with royalties on sales of commercialized therapies leveraging the technology
• The license provides ViiV exclusive access to Halozyme’s rHuPH20 technology for specific HIV targets and provide opportunities to develop ultra-long-acting therapies
• The companies are planning to initiate the first experiments for long acting cabotegravir with the technology to prevent HIV which is expected at the end of 2021

  | Ref: GSK | Image: ViiV